Latest Media Releases

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

CARETEQ Q4-FY22 Activities Report and Appendix 4C (ASX:CTQ)

Highlights: -- Careteq’s pipeline expands five-fold in 4QFY22 vs. the previous quarter with over 60 active leads across the US and Australia -- The Group is generating interest from a wide...read more

CARETEQ - 3Q-FY22 Activities Report & Appendix 4C (ASX:CTQ)

Highlights: * Careteq achieves several milestones in the quarter and advances on significant opportunities in Australia and North America, as highlighted in Careteq’s prospectus * Further ...read more

CARETEQ - Clarification of Appendix 3X & Appendix 3Y - M Simari (ASX:CTQ)

Careteq Limited (ASX: CTQ, “Careteq” or the “Group”) advises the following in relation to the Appendix 3X as lodged for Mr Simari on 11 January 2022: * The Appendix 3X was...read more

Careteq & RMIT sign Research Collaboration Agreement (ASX:CTQ)

Highlights: * Leading Victorian university RMIT University will work with Careteq to develop new assistive living technology solutions to expand on Careteq’s proprietary Sofihub platform *...read more

CARETEQ - Executive Leadership Team Restructured For Growth (ASX:CTQ)

Careteq Limited (ASX:CTQ, "Careteq" or the "Group") is pleased to announce the restructuring of the executive leadership team to better take advantage of the many growth opportun...read more

CARETEQ - Half Year Results Presentation (ASX:CTQ)

To view the presentation, download the attached PDF.

CARETEQ - Appendix 4D & Half Year Results (ASX:CTQ)

Highlights: -- Interim revenue jumps >6 times to $1.9m due to Ward MM acquisition and sharp increase in active SaaS platform users -- Number of users grows 579% pcp to >3k and Ward MM prof...read more

Circadian, Investment Research Report by Analyst Available on Circadian Website (ASX:CIR)

Circadian Technologies (ASX:CIR; OTCQX:CKDXY) announced today that a commissioned reports by a leading healthcare analyst, Edison Investment Research based in London, was published last night and is a...read more

Circadian, Data positive published on performance of Cancers of Unknown Primary Diagnostic Test (ASX:CIR)

- Data shows diagnostic test capable of detecting primary source of cancers with high level of accuracy and specificity across 15 different tumour types. - Commercial launch expected March/April ...read more

Circadian, Operational Achievements and Half-Year Financial Report 31 December 2011 (ASX:CIR)

In accordance with Listing Rule 4.2A, attached is the Half-Year Financial Report (reviewed) on the consolidated results of Circadian Technologies Limited (‘Circadian’ or ‘Group&rs...read more

Circadian, Potential new therapy: VGX-100 identified for improving corneal graft survival (ASX:CIR)

- Data published in the scientific journal Investigative Ophthamology & Visual Science generated by investigators at The Schepens Eye Research Institute led by Harvard University Professor Reza...read more

BIOTECH SHOWCASE PARC 55, SAN FRANCISCO 11 JANUARY 2012 (ASX:CIR)

To view Presentation please download PDF below:

Circadian commences first Phase 1 clinical trial of VEGF-C antibody VGX-100 in cancer patients (ASX:CIR)

Melbourne, Australia January 9 2012 – Circadian Technologies Limited (ASX:CIR, OTCQX:CKDXY) announced today that it has commenced the first Phase 1 clinical trial of its fully human monoclona...read more

CEO on IND status for VGX-100 (ASX:CIR)

In this Open Briefing, CEO & MD Robert Klupacs discusses - Clinical and commercial implications of IND status for VGX-100 - Design, end points and time lines of Phase I trials - Outlook...read more

Circadian receives FDA IND approval to begin clinical trials with VGX-100 for the treatment of cancer patients with solid tumors (ASX:CIR)

Melbourne, Australia October 31, 2011 – Circadian Technologies Limited (ASX: CIR, OTCQX:CKDXY) announces that its 100% owned subsidiary, Vegenics Pty Ltd, has received approval for its invest...read more

Viewing: 31 - 45 of 55 Previous | Next